XML 40 R21.htm IDEA: XBRL DOCUMENT v3.20.2
Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders
 6 Months Ended
Jun. 28, 2020
Earnings Per Share [Abstract]  
Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders
The following table provides the detailed calculation of EPS:
 
 
Three Months Ended
 
Six Months Ended
(IN MILLIONS)
 
June 28,
2020

 
June 30,
2019

 
June 28,
2020

 
June 30,
2019

EPS Numerator––Basic
 
 
 
 
 
 
 
 
Income from continuing operations
 
$
3,434

 
$
5,056

 
$
6,845

 
$
8,945

Less: Net income attributable to noncontrolling interests
 
8

 
10

 
17

 
15

Income from continuing operations attributable to Pfizer Inc.
 
3,426

 
5,046

 
6,828

 
8,929

Less: Preferred stock dividends––net of tax
 
—

 
—

 
—

 
—

Income from continuing operations attributable to Pfizer Inc. common shareholders
 
3,426

 
5,045

 
6,828

 
8,929

Discontinued operations––net of tax
 
—

 
—

 
—

 
—

Net income attributable to Pfizer Inc. common shareholders
 
$
3,426

 
$
5,045

 
$
6,828

 
$
8,929

EPS Numerator––Diluted
 
 

 
 

 
 

 
 

Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions
 
$
3,426

 
$
5,046

 
$
6,828

 
$
8,929

Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions
 
—

 
—

 
—

 
—

Net income attributable to Pfizer Inc. common shareholders and assumed conversions
 
$
3,426

 
$
5,046

 
$
6,828

 
$
8,929

EPS Denominator
 
 

 
 

 
 

 
 

Weighted-average number of common shares outstanding––Basic
 
5,554

 
5,562

 
5,550

 
5,598

Common-share equivalents: stock options, stock issuable under employee compensation plans and convertible preferred stock
 
65

 
110

 
66

 
112

Weighted-average number of common shares outstanding––Diluted
 
5,619

 
5,672

 
5,616

 
5,711

Anti-dilutive common stock equivalents(a)
 
6

 
1

 
4

 
2

(a) 
These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.